Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges☆
Under a Creative Commons license
open access
Abbreviations
2-AI
2-aminoindane
2C-B
2,5-dimethoxy-4-bromophenethylamine
5-IAI
5-iodo-2-aminoindane
COMT
catechol-O-methyl transferase
CPP
conditioned place preference
DAT
dopamine transporter
DIO
diet-induced obese
DMT
N,N-dimethyltryptamine
EAAT2
excitatory amino acid transporter 2
EPPTB
N-(3-ethoxyphenyl)-4-pyrrolidin-1-yl-3-trifluoromethylbenzamide (RO5212773)
FMO3
flavin-containing monooxygenase 3
GirK
G protein-coupled inwardly-rectifying potassium
GLP-1
glucagon like peptide 1
GPCR
G protein-coupled receptor
IUPHAR
International Union of Basic and Clinical Pharmacology
LSD
lysergic acid diethylamide
m-CPP
m-chlorophenylpiperazine
MDMA
3,4-methylenedioxymethamphetamine
NC-IUPHAR
International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification
PANSS
positive and negative symptom scale
phMRI
pharmacological magnetic resonance imaging
SNpc
substantia nigra pars compacta
TAAR
trace amine-associated receptor
VTA
ventral tegmental area
Keywords
Trace amine-associated receptors
Schizophrenia
Addiction
Metabolic disorders
Immune system, Microbiota
Cited by (0)
- ☆
All authors contributed equally to this manuscript.
© 2017 The Authors. Published by Elsevier Inc.